Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Here's the presentation by my friend and colleague Dr. Rogerio Lilenbaum, a great medical oncologist now serving as Director of Hematology/Oncology at the Cleveland Clinic Foundation in South Florida (Weston, FL). Though he's been renowned in lung cancer in general for many years, he's best known for his particular knowledge and leadership on the topic of managing lung cancer in elderly and frail (variably referred to as poor risk or poor performance status) patients.
Here is his talk, in audio and video podcast format, along with the associated figures and transcript:
[powerpress]
dr-lilenbaum-on-treating-lung-cancer-in-elderly-pts-audio-podcast
dr-lilenbaum-on-treating-lung-cancer-in-elderly-pts-figs
dr-lilenbaum-on-treating-lung-cancer-in-elderly-pts-transcript
His presentation includes a general perspective on principles of treating elderly patients and how we should be making recommendations, along with a summary of the evidence on chemotherapy for patients with resected early stage NSCLC, locally advanced NSCLC, and advanced/metastatic disease. It's a great overview of a big topic, and I hope it's very helpful.
We'll follow with a podcast of the live question and answer session that followed his presentation.
Thanks to LUNGevity Foundation for partnering with GRACE to develop this program.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…